Join to view full profile
5776-D Lindero Canyon Rd, Ste 320Thousand Oaks, CA 91362
Phone+1 415-420-3454
Dr. Benjamin is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Jonathan Benjamin, MD, PhD, is a hematologist/oncologist based in Thousand Oaks, CA. He completed his residency in Internal Medicine at the University of California, San Francisco after graduating from the New York University School of Medicine in 2001. Currently, he serves as a Principal at JB R&D Consulting. Dr. Benjamin has held significant roles, including Chief Medical Officer at ImmPACT Bio and SVP of Clinical Research at Atreca, Inc. His expertise lies in areas such as leukemia, lymphoma, and medical oncology. He has authored numerous impactful publications, one of which was cited 600 times, and participated in the design and execution of multiple clinical trials of biologics, cell therapies, and small molecules.
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 2001 - 2004
New York University School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2003 - 2027
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Start of enrollment: 2009 May 01
- Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2010 Nov 01
- Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Start of enrollment: 2011 Mar 01
Publications & Presentations
PubMed
- 20 citationsDonor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms.Rupa Narayan, Jonathan Benjamin, Omid Shah, Lu Tian, Keri Tate
Biology of Blood and Marrow Transplantation. 2019-07-01 - 638 citationsBlinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemiaNicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux
Blood. 2018-04-05 - 20 citationsBlinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.Max S. Topp, M Stelljes, Gerhard Zugmaier, Phillip Barnette, Leonard T. Heffner
Leukemia. 2018-02-01
Press Mentions
13 Discoveries in the Last Year Have Fundamentally Altered Our Understanding of Human HistoryDecember 11th, 2020
Professional Memberships
- Member
- Member
- American Society for Blood and Marrow TransplantationMember
Industry Relationships
- Vice President Clinical Research, Atreca, Inc2017 - Present
- Medical Director, Amgen2014 - 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
